logo-loader
viewPharmaxis Ltd

Pharmaxis sees progress in Boehringer Ingelheim’s clinical trial in patients with NASH

Boehringer Ingelheim has completed enrolment of the Phase 2a clinical trial of a Pharmaxis developed drug in NASH.

clinical trial
The trial is expected to report in the second half of 2019

Pharmaxis Ltd (ASX:PXS) is looking forward to the results from Boehringer Ingelheim’s Phase 2a clinical trial in patients with non‐alcoholic steatohepatitis (NASH).

Boehringer Ingelheim has completed enrolment of the trial which is assessing BI 1467335 that works by blocking leucocyte adhesion and tissue infiltration in inflammatory processes underlying NASH.

BI 1467335 was acquired from Pharmaxis in May 2015 and is also in an ongoing Boehringer Ingelheim Phase 2a clinical trial for diabetic retinopathy.

Whilst Pharmaxis will not receive any milestone payments for a positive Phase 2a trial result under its contract with Boehringer Ingelheim, a positive result will increase the likelihood of receiving future milestones with the next one being triggered by the start of a phase 3 study.

Phase 2a expected to report in the second half of 2019

The Phase 2a NASH trial is a multi‐centre, double‐blind design in 114 patients with clinical evidence of NASH. The trial is being conducted in nine countries across North America and Europe.

The primary objectives are to establish proof of clinical principle, investigate suitable dosing, and to evaluate the safety of BI 1467335.

Patients have been randomized to either one of four dosages of BI 1467335 or to placebo for a 12‐week treatment period followed by a 4‐week observation period.  

The trial is expected to report in the second half of 2019. A subsequent Phase 2b study will seek to confirm and extend these findings.  

NASH is a major cause of liver fibrosis

Non‐alcoholic fatty liver disease (NAFLD), the most common liver disorder in Western industrialized nations, and its more serious form NASH, is highly prevalent amongst patients with type 2 Diabetes.

NASH is a major cause of liver fibrosis and cirrhosis and is an area of high unmet medical need with no treatments currently available.

The high prevalence of type 2 diabetes and obesity is expected to make NASH one of the most common causes of advanced liver disorders in the coming decades.

25% of the general adult population in the world has NAFLD and the prevalence of NASH has been found to range from 1.5% to 6.45% in current research, a number twice as high as 20 years ago.

READ: Pharmaxis well funded as potential partners assess its anti‐fibrotic mechanisms

Pharmaxis CEO Gary Phillips said: “We are delighted to see the progress made on this study and look forward to this trial reporting in the second half of this year.

“Whilst we do not receive any milestone payments under our contract with Boehringer Ingelheim for a positive trial result, this will still be the first proof of clinical principle of the Pharmaxis drug acquired in 2015.

“A positive result will increase the likelihood of receiving future milestones with the next one being triggered by the start of a phase 3 study.”

Quick facts: Pharmaxis Ltd

Price: 0.23 AUD

ASX:PXS
Market: ASX
Market Cap: $90.77 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Pharmaxis hopeful of FDA approval for cystic fibrosis inhalation medicine...

Pharmaxis Ltd (ASX:PXS) chief executive officer Gary Phillips updates Proactive Investors on the FDA approval timeframe for the company’s Bronchitol inhalation medicine used to treat adult cystic fibrosis patients. The healthcare-focused company is confident it will meet information...

on 13/8/19

3 min read